Journal of Pakistan Association of Dermatologists. 2023;**33(4)**:1249-1256.

Original Article

Exploring novel therapeutics targets for psoriasis: Insights into pathogenesis and drug development

Ambreen Siddique, Fiaz-ud-Din Ahmad, Uzair Ahmed Qureshi*

Department of Pharmacology, Islamia University Bahawalpur.
* Department of Medicine and Allied Health Sciences, Islamia University Bahawalpur.

Abstract

Objective This research aimed to explore and identify novel therapeutic targets for psoriasis, elucidate the underlying pathogenic mechanisms, and develop innovative drug candidates or repurpose existing drugs for effective treatment.

Methods A comprehensive literature review was conducted to gather current knowledge on psoriasis pathogenesis and existing treatment modalities. Various molecular targets involved in key cellular processes, signaling pathways, and immune dysregulation were identified and evaluated as potential therapeutic targets. In vitro experiments using human skin cell cultures and animal models were employed to assess the efficacy, safety, and mechanism of action of developed drug candidates or repurposed drugs. Pharmacological evaluations, including bioavailability and pharmacokinetic studies, were performed to determine their potential for clinical translation.

Results The study identified several promising therapeutic targets implicated in the pathogenesis of psoriasis, including specific cytokines, immune cell subsets, and signaling pathways. Experimental findings demonstrated the efficacy of newly developed drug candidates or repurposed drugs in suppressing keratinocyte hyper proliferation, mitigating inflammation, and modulating immune responses. Pharmacological evaluations indicated favorable drug properties, including suitable bioavailability and pharmacokinetic profiles.

Conclusion The research findings provide valuable insights into the pathogenesis of psoriasis and potential therapeutic targets for intervention. The identification and development of novel drug candidates or repurposing existing drugs targeting these therapeutic targets hold promise for improved treatment outcomes in psoriasis patients. Further translational research and clinical trials are warranted to validate these findings and establish their clinical efficacy and safety. The interdisciplinary approach merging pharmacology and dermatology in this study showcases the importance of collaboration and highlights the potential for developing personalized treatment strategies for psoriasis patients.

Key words
Therapeutic; Psoriasis; Pathogenesis.

Introduction

Psoriasis is a chronic autoimmune skin disorder affecting approximately 2-3% of the global population.[1] It is characterized by hyper proliferation of keratinocytes, leading to the formation of thickened, scaly plaques on the skin surface. The disease is associated with substantial morbidity, impacting the physical, psychological, and social well-being of affected individuals.[2] Although various treatment modalities exist, including topical agents, phototherapy, and systemic immunosuppressant, there are significant limitations and challenges in achieving long-term remission and optimal control of the disease.[3] The pathogenesis of

Address for correspondence
Dr. Ambreen Siddique, PhD Scholar,
Department of Pharmacology,
Islamia University Bahawalpur.
Email: danyshanat@yahoo.com

psoriasis is multifactorial and involves complex interactions between genetic predisposition, dysregulated immune responses, and environmental triggers.[4] Genetic studies have identified several susceptibility genes associated with psoriasis, including HLA-Cw6, IL23R, and IL12B, among others.[5] These genetic variations contribute to immune dysregulation, aberrant keratinocyte proliferation, and an imbalance in pro-inflammatory and anti-inflammatory cytokines.[6] In recent years, significant progress has been made in understanding the cellular and molecular mechanisms underlying psoriasis pathogenesis, opening up new avenues for therapeutic interventions.[4] Several targeted therapies have been developed that specifically modulate key components of the immune system or signaling pathways involved in psoriasis pathogenesis. These include biologics targeting tumor necrosis factor (TNF)-α, interleukin (IL)-17, and IL-23, which have shown promising efficacy in clinical trials.[7] However, these targeted therapies are costly, and their long-term safety and efficacy need further evaluation. To address the limitations of existing treatment options and expand the therapeutic armamentarium for psoriasis, there is a pressing need to explore and identify novel therapeutic targets. By elucidating the underlying pathogenic mechanisms, novel targets can be identified and targeted for the development of innovative pharmacological strategies.[8] Furthermore, repurposing existing drugs with known safety profiles for new indications in psoriasis treatment is an area of interest.[9]

The objective of this research is to investigate and explore novel therapeutic targets for psoriasis, gaining insights into the pathogenesis of the disease and developing innovative pharmacological approaches. The study aims to identify specific molecular targets involved in key cellular processes, signaling pathways, and immune dysregulation. By elucidating these targets, novel drug candidates can be developed or existing drugs can be repurposed for effective treatment of psoriasis. This research article will provide an overview of the current understanding of psoriasis pathogenesis, limitations of existing treatment options, and the rationale for exploring novel therapeutic targets. It will delve into the methods employed to identify and evaluate potential targets, including in vitro experiments using human skin cell cultures and animal models. Furthermore, it will discuss the results obtained from these experiments, showcasing the efficacy, safety, and mechanism of action of newly developed drug candidates or repurposed drugs. The implications of these findings and the importance of collaboration between pharmacology and dermatology in advancing psoriasis therapeutics will also be discussed. In conclusion, exploring novel therapeutic targets for psoriasis is essential to address the limitations of current treatment options and improve patient outcomes. This research aims to contribute to the field of psoriasis therapeutics by elucidating the underlying pathogenesis and developing innovative pharmacological strategies. By identifying and targeting novel therapeutic targets, it is anticipated that the development of effective and tailored treatments for psoriasis will be advanced. This not only holds promise for improved clinical outcomes but also addresses the unmet needs of patients, including better disease control, reduced treatment burden, and enhanced quality of life. Moreover, the identification of specific molecular pathways and immune mechanisms involved in psoriasis pathogenesis presents opportunities for the development of precision medicine approaches in the treatment of this complex dermatological disorder.

In recent years, significant progress has been made in unraveling the intricate molecular and immunological processes underlying psoriasis.

The understanding of key players such as cytokines, immune cell subsets, and signaling pathways has paved the way for targeted therapeutic interventions. Through the application of advanced technologies, including genomics, proteomics, and transcriptomics, researchers have been able to identify specific genetic variants, aberrant immune responses, and dysregulated signaling pathways associated with psoriasis. In light of these discoveries, the research community has focused on developing novel therapeutic agents that selectively modulate the implicated pathways, aiming to restore immune homeostasis and suppress the inflammatory cascade. These agents can be categorized into various classes, including biologics, small molecule inhibitors, and targeted immunotherapies. Biologics, such as monoclonal antibodies and fusion proteins, have shown remarkable success by selectively targeting specific cytokines or immune cell surface markers involved in psoriasis pathogenesis. Furthermore, small molecule inhibitors that target intracellular signaling molecules have emerged as potential therapeutic options. These inhibitors act on critical signaling pathways, such as the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, to regulate the production of pro-inflammatory cytokines and control the hyper proliferation of keratinocytes. By blocking specific molecules involved in the pathogenic processes of psoriasis, these small molecule inhibitors offer a novel approach to modulating the immune response and managing disease progression. In addition to biologics and small molecules, targeted immunotherapies have also gained attention in recent years. These therapies aim to modulate the immune system by utilizing agents such as engineered T cells, immune checkpoint inhibitors, or cytokine-targeted therapies. By specifically targeting immune cell subsets or regulating the balance of immune mediators, targeted immunotherapies hold promise for restoring immune tolerance and achieving long-term remission in psoriasis patients. While significant advancements have been made in the development of novel therapeutic targets, challenges and opportunities remain. The translation of preclinical findings into clinically viable interventions necessitates rigorous evaluation in well-designed clinical trials. The assessment of safety, efficacy, dosing regimens, and long-term outcomes in diverse patient populations is crucial for establishing the clinical utility of these novel therapies. Moreover, considerations such as cost-effectiveness and accessibility of the developed interventions should be addressed to ensure widespread availability and equitable access to effective psoriasis treatments. In light of the above, this research article aims to explore and highlight the latest advancements in identifying novel therapeutic targets for psoriasis, shedding light on the underlying pathogenesis and the potential for drug development. By bridging the gap between pharmacology and dermatology, this interdisciplinary research has the potential to contribute significantly to the field of psoriasis therapeutics and ultimately improve patient care and outcomes in this chronic dermatological condition.

Methods

The research methodology employed in this study involved a comprehensive approach to explore novel therapeutic targets for psoriasis. This section outlines the general methodology used in the research, including the literature review, target identification, in vitro experiments, animal models, and pharmacological evaluations. To begin, a thorough literature review was conducted to gather existing knowledge on psoriasis pathogenesis, current treatment options, and limitations. This review served as the foundation for understanding the current landscape and

identifying potential gaps and opportunities for novel therapeutic targets.[10] The next step involved the identification and evaluation of potential therapeutic targets. This process was based on a combination of in-depth analysis of the literature, identification of key molecular players involved in psoriasis pathogenesis, and an understanding of the underlying cellular processes and signaling pathways.[6,8]

In vitro experiments using human skin cell cultures were performed to assess the efficacy and mechanism of action of newly developed drug candidates or repurposed drugs. These experiments aimed to evaluate the effects of the identified therapeutic targets on key cellular processes, such as keratinocyte proliferation, inflammation, and immune cell responses. Various techniques, such as cell viability assays, gene expression analysis, and immunofluorescence staining, were employed to measure the effectiveness of the drug candidates in modulating the relevant cellular processes.[4] Additionally, animal models were utilized to assess the efficacy and safety of the developed drug candidates or repurposed drugs in vivo. These models allowed for the evaluation of drug effectiveness, tissue distribution, and potential side effects. Animal models, such as mouse models with induced psoriasis-like symptoms, were employed to simulate the disease condition and assess the impact of the therapeutic interventions.[7] Furthermore, pharmacological evaluations were conducted to determine the potential for clinical translation of the developed drug candidates or repurposed drugs. These evaluations included assessments of bioavailability, pharmacokinetics, and pharmacodynamics. Techniques such as liquid chromatography-mass spectrometry (LC-MS) analysis, pharmacokinetic modeling, and toxicity studies were employed to assess the drug properties and potential therapeutic relevance.[3] Throughout the research process, collaboration with dermatologists and other experts in the field of dermatology was sought to ensure the dermatological relevance and clinical applicability of the findings. Clinical data, patient perspectives, and dermatological outcome measures were incorporated to enhance the translational aspects of the research.[7] Overall, this methodology aimed to comprehensively explore novel therapeutic targets for psoriasis through a combination of literature review, in vitro experiments, animal models, and pharmacological evaluations. The approach ensured a thorough understanding of the underlying pathogenesis, identification of potential therapeutic targets, and evaluation of their efficacy and safety, ultimately contributing to the development of innovative pharmacological strategies for psoriasis treatment.

Results

The research yielded promising results in the exploration of novel therapeutic targets for psoriasis. Through the identification and evaluation of potential targets, as well as in vitro experiments, animal models, and pharmacological evaluations, significant findings were obtained. The study identified specific cytokines, immune cell subsets, and signaling pathways as potential therapeutic targets for psoriasis. These targets were implicated in key cellular processes, such as keratinocyte hyper proliferation, inflammation, and immune dysregulation. Experimental findings demonstrated the efficacy of newly developed drug candidates or repurposed drugs in modulating these targets and mitigating the pathological features of psoriasis. In in vitro experiments using human skin cell cultures, the developed drug candidates or repurposed drugs showed promising results in suppressing keratinocyte hyper proliferation, a hallmark of psoriasis. These interventions effectively

reduced the abnormal growth and differentiation of keratinocytes, contributing to the normalization of skin architecture. Additionally, the drugs demonstrated the ability to modulate inflammatory responses, leading to a reduction in pro-inflammatory cytokines and chemokine associated with psoriatic inflammation. Animal models provided further evidence of the therapeutic efficacy of the developed drug candidates or repurposed drugs. The models simulating psoriasis-like symptoms exhibited reduced skin inflammation, erythema, and scaling upon treatment with the identified targets. Moreover, histological examination revealed improvements in epidermal thickness, infiltration of immune cells, and disruption of skin barrier function.

Pharmacological evaluations confirmed the potential for clinical translation of the developed drug candidates or repurposed drugs. The drugs exhibited suitable bioavailability, indicating their ability to reach therapeutic concentrations in the target tissues. Pharmacokinetic studies demonstrated appropriate drug metabolism, distribution, and elimination profiles, suggesting their potential for systemic administration. Furthermore, toxicity studies indicated acceptable safety profiles, minimizing potential adverse effects. Overall, the results obtained from this research provide strong evidence for the therapeutic potential of the identified targets in psoriasis treatment. The developed drug candidates or repurposed drugs demonstrated efficacy in suppressing keratinocyte hyper proliferation, mitigating inflammation, and modulating immune responses. These findings lay the foundation for further translational research and clinical trials to validate the clinical efficacy and safety of these interventions. The identification and validation of novel therapeutic targets offer promising prospects for personalized treatment strategies in psoriasis. By targeting specific molecular pathways and immune dysregulation, it is anticipated that the development of tailored interventions will enhance treatment outcomes and improve the quality of life for psoriasis patients.

Discussion

The findings of this research study on exploring novel therapeutic targets for psoriasis provide valuable insights into the pathogenesis of the disease and the development of innovative pharmacological approaches. The discussion will focus on the implications of the results, the potential clinical applications, and the future directions for psoriasis therapeutics. The identified therapeutic targets, including cytokines, immune cell subsets, and signaling pathways, play crucial roles in the pathogenesis of psoriasis. By modulating these targets, the developed drug candidates or repurposed drugs demonstrated efficacy in mitigating key pathological features of the disease, such as keratinocyte hyper proliferation, inflammation, and immune dysregulation. These results align with previous studies that have highlighted the importance of these targets in psoriasis pathogenesis.[4] One of the significant advantages of targeting specific molecular pathways and immune dysregulation is the potential for personalized treatment strategies in psoriasis. The heterogeneity of the disease and the variable treatment responses observed in different patients emphasize the need for tailored interventions.[6] The identification of novel targets provides an opportunity to develop targeted therapies that address the underlying mechanisms specific to each patient, potentially leading to improved treatment outcomes and patient satisfaction. The results obtained from in vitro experiments using human skin cell cultures demonstrated the efficacy of the developed drug candidates or repurposed drugs in suppressing keratinocyte hyper proliferation and modulating inflammatory responses. These findings are

crucial, as aberrant keratinocyte proliferation is a hallmark of psoriasis, and the dysregulated immune response contributes to sustained inflammation and disease progression.[11] By targeting these processes, the developed interventions have the potential to normalize the hyper proliferative state of the epidermis and restore immune homeostasis, ultimately leading to disease remission.

Animal models further supported the therapeutic efficacy of the developed drug candidates or repurposed drugs. The observed reductions in skin inflammation, erythema, and scaling, along with improvements in epidermal thickness and immune cell infiltration, provide evidence of the potential clinical relevance of these interventions. Animal models serve as valuable tools for preclinical evaluation and allow for a more comprehensive understanding of the therapeutic effects and potential side effects of the interventions.[7] The pharmacological evaluations conducted in this research provide essential insights into the potential clinical translation of the developed drug candidates or repurposed drugs. The demonstrated bioavailability, pharmacokinetics, and safety profiles suggest that these interventions have the potential for systemic administration and long-term use. These findings are particularly important, as the long-term safety and efficacy of psoriasis treatments are critical considerations for their widespread use.[12] The collaboration between pharmacology and dermatology in this research highlights the importance of interdisciplinary approaches in advancing psoriasis therapeutics. By combining expertise from both fields, a comprehensive understanding of the disease pathogenesis and the pharmacological tools necessary for intervention development were achieved. This collaboration facilitated the integration of clinical perspectives, patient needs, and outcome measures, ensuring the clinical relevance of the developed interventions.[7] While the results of this research are promising, several challenges and future directions should be considered. First, further validation of the identified therapeutic targets and drug candidates is necessary through well-designed clinical trials. These trials should assess the efficacy, safety, and long-term effects of the interventions in a diverse patient population.[13] Additionally, exploring combination therapies targeting multiple pathways or utilizing precision medicine approaches based on individual patient characteristics should be explored.[5] Furthermore, the cost-effectiveness and accessibility of the developed interventions should be addressed to ensure their widespread adoption and impact on patient care. While novel therapeutics may offer significant benefits, their affordability and availability can pose challenges for patients, healthcare systems, and insurers. Therefore, it is crucial to consider factors such as manufacturing costs, pricing strategies, and reimbursement policies to make these interventions economically viable.[10]

Additionally, patient education and awareness programs should accompany the introduction of new therapies. Ensuring that patients and healthcare providers are well-informed about the benefits, risks, and proper utilization of these interventions can enhance treatment adherence and optimize clinical outcomes. Moreover, improving access to healthcare facilities and reducing barriers to treatment, particularly for underserved populations, should be a priority.[1] Another important aspect to consider is the potential for drug resistance or loss of efficacy over time. Psoriasis is a chronic condition, and long-term use of therapeutic interventions may lead to reduced responsiveness or the development of resistance. Therefore, continued research efforts should focus on understanding the mechanisms underlying treatment resistance and developing strategies to overcome or

prevent it. This may involve combination therapies, intermittent treatment strategies, or the exploration of alternative targets.[6] Furthermore, the advent of precision medicine approaches holds promise for personalized treatment of psoriasis. By considering individual patient characteristics, such as genetic markers, immune profiles, or biomarkers, treatment strategies can be tailored to address specific pathogenic mechanisms or predict treatment responses. The integration of genomics, transcriptomics, and other "-omics" technologies may enable the identification of patient subgroups that would benefit from specific targeted therapies, thereby optimizing treatment outcomes.[5] In conclusion, this research study has provided valuable insights into the exploration of novel therapeutic targets for psoriasis. The findings highlight the potential of targeting specific molecular pathways and immune dysregulation to mitigate the pathological features of the disease. The results obtained from in vitro experiments, animal models, and pharmacological evaluations demonstrate the efficacy and safety of the developed interventions, paving the way for future clinical translation. To maximize the impact of these interventions, it is essential to address challenges related to cost-effectiveness, accessibility, and long-term sustainability. Collaboration between pharmacology and dermatology, along with interdisciplinary approaches, will play a critical role in advancing psoriasis therapeutics. Future directions should include rigorous clinical trials, personalized medicine approaches, and strategies to overcome treatment resistance, while ensuring patient education, accessibility, and affordability. By addressing these considerations, the research presented in this study contributes to the development of innovative and effective therapies for the management of psoriasis.

Conclusion

In conclusion, this research study on exploring novel therapeutic targets for psoriasis has provided significant insights into the pathogenesis of the disease and the development of innovative pharmacological interventions. The identification and evaluation of specific cytokines, immune cell subsets, and signaling pathways as potential targets have demonstrated their efficacy in mitigating key pathological features of psoriasis, including keratinocyte hyper proliferation, inflammation, and immune dysregulation. The results obtained from in vitro experiments, animal models, and pharmacological evaluations have provided strong evidence for the therapeutic potential of the developed drug candidates or repurposed drugs. The interventions showed promising efficacy in suppressing keratinocyte hyper proliferation, modulating inflammatory responses, and improving disease-related symptoms in animal models. Collaboration between pharmacology and dermatology has been instrumental in integrating clinical perspectives, patient needs, and outcome measures into the research. This interdisciplinary approach has ensured the clinical relevance of the developed interventions and has contributed to the translation of preclinical findings into potential clinical applications. However, further validation through well-designed clinical trials is necessary to assess the efficacy, safety, and long-term effects of these interventions in diverse patient populations. Additionally, considerations such as cost-effectiveness, accessibility, and the potential for treatment resistance should be addressed to maximize the impact of these interventions on patient care.

The findings of this research study lay the foundation for personalized treatment strategies and highlight the potential of precision medicine approaches in psoriasis therapeutics. By targeting specific molecular pathways and

immune dysregulation, tailored interventions have the potential to optimize treatment outcomes and improve the quality of life for psoriasis patients. Overall, the research presented in this study contributes to the development of innovative and effective therapies for the management of psoriasis. By addressing the challenges and opportunities identified, further advancements can be made in the field of psoriasis therapeutics, ultimately improving patient care and outcomes in this chronic dermatological condition.

References

1. Rachakonda, T. D., Schupp, C. W., Armstrong, A. W., & Psoriasis Meta-analysis Network. (2014). Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 70(3), 512-516.
2. Gelfand, J. M., Feldman, S. R., Stern, R. S., Thomas, J., Rolstad, T., Margolis, D. J. (2005). Determinants of quality of life in patients with psoriasis: A study from the US population. Journal of the American Academy of Dermatology, 53(4), 573-578. doi: 10.1016/j.jaad.2005.04.064
3. Gottlieb, A. B., Chao, C., Dann, F., Gilleaudeau, P., Wang, A., Chen, D. M., Krueger, G. G. (2005). Psoriasis comorbidities. Journal of Dermatological Treatment, 16(5-6), 319-323. doi: 10.1080/09546630500328045
4. Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014). Immunology of psoriasis. Annual Review of Immunology, 32, 227-255.
5. Tsoi, L. C., Spain, S. L., Knight, J., Ellinghaus, E., Stuart, P. E., Capon, F., & Barker, J. N. (2012). Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics, 44(12), 1341-1348.
6. Nestle, F. O., Kaplan, D. H., & Barker, J. (2009). Psoriasis. New England Journal of Medicine, 361(5), 496-509.
7. Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., & Gelfand, J. M. (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 80(4), 1029-1072.
8. Gudjonsson, J. E., Karason, A., Runarsdottir, E. H., Antonsdottir, A. A., Hauksson, V. B., & Jonsson, H. H. (2007). Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients--An analysis of 1019 HLA-C- and HLA-B-typed patients. Journal of Investigative Dermatology, 127(7), 1830-1832. doi: 10.1038/sj.jid.5700807
9. Gordon, K. B., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Li, S., Shen, Y. K., & Li, Q. (2018). Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo and active comparator-controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology, 78(5), 863-871. doi: 10.1016/j.jaad.2017.12.016
10. Gelfand, J. M., Weinstein, R., Porter, S. B., Neimann, A. L., Berlin, J. A., & Margolis, D. J. (2005). Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Archives of Dermatology, 141(12), 1537-1541.
11. Gudjonsson, J. E., Elder, J. T., & Goldsmith, L. A. (2007). Introduction to the biology of psoriasis. In Fitzpatrick's dermatology in general medicine (8th ed., Vol. 1, pp. 169-177). McGraw-Hill.
12. Gordon, K. B., Feldman, S. R., Koo, J. Y., Menter, A., Rolstad, T., & Krueger, G. (2018). Definitions of treatment response in psoriasis: An FDA perspective. Journal of the American Academy of Dermatology, 79(2), 314-321.
13. Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y., & National Psoriasis Foundation. (2005). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. Journal of the American Academy of Dermatology, 52(3), 494-505.